Search Articles — Sudonull

Search Results

From other projects

Teplizumab approved for children: delaying type 1 diabetes

https://ymaho.com/teplizumab-approved-for-children-delaying-type-1-diabetes

FDA approved teplizumab for children from 1 year old. Learn how disease-modifying therapy changes the treatment paradigm for type 1 diabetes. Detailed analysis.

Tzield approved for children from 1 year: delaying type 1 diabetes

https://ymaho.com/tzield-approved-for-children-from-1-year-delaying-type-1-diabetes

FDA expanded indications for teplizumab to children from one year. First drug capable of delaying diabetes for years at the preclinical stage. Learn how infusions change the prognosis for infants.

Fungi shape immunity and metabolism in newborns | NIH Study

https://ymaho.com/fungi-shape-immunity-and-metabolism-in-newborns-nih-study

NIH study in Science: fungus Candida dubliniensis is critical for pancreatic beta-cell development and diabetes prevention. Learn how this changes neonatal medicine.

Survodutide in obesity: 13% efficacy in phase 3

https://ymaho.com/survodutide-in-obesity-13-efficacy-in-phase-3

The new dual agonist Survodutide showed 13% weight reduction in patients with obesity without diabetes. Learn about the mechanism of action, side effects, and prospects of the drug.

How to quickly lower A1C: 5 scientific strategies

https://lrivo.com/how-to-quickly-lower-a1c-5-scientific-strategies

Learn how to quickly lower HbA1c with intermittent fasting, Mediterranean diet, and technology. A science-based 3-month action plan.

Langlara: FDA approved Chinese insulin biosimilar

https://ymaho.com/langlara-fda-approved-chinese-insulin-biosimilar

FDA approved interchangeable biosimilar insulin glargine Langlara from Chinese Sunshine Lake. Learn how this will change the US market and prices for patients. Detailed analysis inside.

FDA to Review Afrezza: First Needle-Free Insulin for Children

https://ymaho.com/fda-to-review-afrezza-first-needle-free-insulin-for-children

On May 29, 2026, the FDA will decide on Afrezza inhaled insulin for children aged 4–17. Learn why this is a market shift and a chance for a needle-free life. Read the analysis.

Trending Now